Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

p53 negatively regulates expression of FoxM1.

Pandit B, Halasi M, Gartel AL.

Cell Cycle. 2009 Oct 15;8(20):3425-7. Epub 2009 Oct 25.

PMID:
19806025
2.

Molecular interactions of polo-like kinase 1 in human cancers.

Weng Ng WT, Shin JS, Roberts TL, Wang B, Lee CS.

J Clin Pathol. 2016 Jul;69(7):557-62. doi: 10.1136/jclinpath-2016-203656. Epub 2016 Mar 3. Review.

PMID:
26941182
3.

FOX(M1) news--it is cancer.

Halasi M, Gartel AL.

Mol Cancer Ther. 2013 Mar;12(3):245-54. doi: 10.1158/1535-7163.MCT-12-0712. Epub 2013 Feb 26. Review.

4.

Targeting FOXM1 in cancer.

Halasi M, Gartel AL.

Biochem Pharmacol. 2013 Mar 1;85(5):644-52. doi: 10.1016/j.bcp.2012.10.013. Epub 2012 Oct 24. Review.

PMID:
23103567
5.

A new target for proteasome inhibitors: FoxM1.

Gartel AL.

Expert Opin Investig Drugs. 2010 Feb;19(2):235-42. doi: 10.1517/13543780903563364. Review.

6.

FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways.

Kelleher FC, O'Sullivan H.

Oncotarget. 2016 Jul 5;7(27):42792-42804. doi: 10.18632/oncotarget.8669. Review.

7.

Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors.

Gartel AL.

Scientifica (Cairo). 2014;2014:596528. doi: 10.1155/2014/596528. Epub 2014 Jun 24. Review.

8.

Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Song X, Fiati Kenston SS, Zhao J, Yang D, Gu Y.

Med Oncol. 2017 Mar;34(3):41. doi: 10.1007/s12032-017-0888-3. Epub 2017 Feb 8. Review.

PMID:
28176242
9.

FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance.

Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW.

Biochim Biophys Acta. 2014 Nov;1839(11):1316-22. doi: 10.1016/j.bbagrm.2014.09.016. Epub 2014 Oct 5. Review.

Supplemental Content

Support Center